Ikarovec has presented preclinical evidence for IKAR-001, a dual-pathway gene therapy designed to combine complement ...

Biogen has announced a definitive agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion, a move that would expand its presence in complement-mediated diseases, including ...

German company Complement Therapeutics, which has a research laboratory at Stevenage Bioscience Catalyst, reports that the ...